First Oral Therapy for Rare Adrenal Gland Tumors Gets Green Light From FDA

MSD adds new indication for Welireg in rare tumours

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'

First Oral Therapy for Rare Adrenal Gland Tumors Gets Green Light From FDA

(MedPage Today) -- The FDA has expanded the approval of belzutifan (Welireg) to include certain types of pheochromocytoma or paraganglioma (PPGL) in adults and children. The action establishes belzutifan as the only approved oral therapy for PPGL...

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with advanced PPGL RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult and pediatric patients 12 years and o…

Dr Perez on the FDA Approval of Belzutifan for Advanced Pheochromocytoma and Paraganglioma

Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

FDA Approves Belzutifan in Advanced Pheochromocytoma and Paraganglioma

The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in patients 12 years and older.

FDA Approves Welireg for Pheochromocytoma and Paraganglioma

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.